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yet. Taking into consideration the variety of HRQoL tools and data available, more 
options could be explored to identify the most sensitive utility approach.
PMS99
The Burden of rheuMaToid arThriTiS in ruSSia
Pedersini R1, Karateev DE2, Vasilescu RS3, Alvir JM4, Spurden D5, Smolen JS6
1Kantar Health, Epsom, UK, 2V.A. Nasonova Research Institute of rheumatology, Moscow, Russia, 
3Pfizer Inc., Brussels, Belgium, 4Pfizer, Inc., New York, NY, USA, 5Pfizer Inc., Kingston Upon 
Thames, UK, 6Medical University of Vienna, Vienna, Austria
Objectives: The enormous socioeconomic impact of rheumatoid diseases has 
been increasingly studied in the USA and Europe. The objective of this study is to 
determine the burden of RA in Russia, focusing on outcomes such as health-related 
quality of life (QoL: EQ-5D, HAQ-DI), work productivity (WPAI) and use of health-
care resources (healthcare provider, hospital and emergency visits). MethOds: A 
cross-sectional cohort of 408 adult patients with a diagnosis of RA for at least 12 
months were recruited in 2013-2014 by 51 rheumatologists, in Moscow and 12 other 
Russian regions. Patients with concomitant Crohn’s disease, psoriasis or other forms 
of arthritis were excluded. Subjects underwent an assessment of their RA status 
(previous 12 months to current). General linear models predicted outcomes while 
controlling for main predictors (current treatment, region, current disease activity 
– DAS28) and covariates (sociodemographics, RA activity in past week). Results: 
Most patients were female (78%), recruited in Moscow (43%) and followed by public 
hospitals (90%). Half were at radiologic stage II, overweight, at functional class 2 
and with an invalidity pension; 74% had moderate and 22% severe disease activity 
(DAS28). Current EQ-5D and HAQ-DI scores showed significant impairment (0.6, 
1.4); patients reported on average 15% absenteeism, 21% presenteeism, 24% over-
all work impairment and 49% activity impairment; over the past 12 months, on 
average they visited a rheumatologist 6 times, 17% were hospitalised and 2% had 
emergency visits. While patients in Moscow reported lower QoL, they also had lower 
absenteeism and resource use. RA activity in past week was strongly associated with 
all outcomes. cOnclusiOns: The majority of Russian RA patients had moderate 
activity and poor outcomes. While there was no significant difference in private vs. 
public hospitals, Moscow patients reported lower absenteeism and resource use 
than the other regions combined.
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Objectives: Gout is often overlooked despite the pain caused by acute flares and 
the joint damage caused by the development of debilitating tophi (deposits of uric 
acid crystals). The study objective was to review and summarise the current evi-
dence of the disease burden of chronic gout, in relation to health-related quality of 
life (HRQL), and to identify key factors correlated with an increased disease burden. 
Our primary aim was to support the economic evaluation of new treatments for 
gout. In addition, we identified key data gaps that may need further investiga-
tion. MethOds: A systematic literature review was conducted using the MEDLINE 
database and The Cochrane Library. Articles published in English between January 
2000 and July 2014 that reported the humanistic burden (HRQL and/or utility) of gout 
were identified. Key data were extracted and summarised, with key themes and data 
gaps identified. Results: Searches identified 323 studies, of which 21 were relevant 
to the humanistic burden of gout. The humanistic burden was largely due to physical 
disability and pain resulting from chronic clinical manifestations. Utility weights, 
as assessed by Short Form 6 dimensions, were estimated at 0.53 for a patient with 
severe gout (3+ flares/year and tophi) and 0.73 for an asymptomatic patient with 
serum uric acid levels < 6mg/dL. cOnclusiOns: The evidence confirms that gout 
represents a significant burden in terms of HRQL. A reported growing prevalence 
means this is likely to be of considerable concern for healthcare decision makers. 
In light of this, effective urate-lowering treatments are likely to be valued, if they 
can be clearly demonstrated to be both clinically effective and cost effective. There 
is a need to develop a comprehensive set of comparative HRQL utility assessments, 
especially in non-US countries.
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Objectives: The aim of this study was to investigate the socio-economic impact of 
chronic autoimmune diseases, mainly rheumatoid arthritis (RA) and work disabilities, 
among patients in Slovakia. MethOds: Patients were prospectively recruited in the 
National Institute for Rheumatic Diseases in 2014 – 2015 and the data were collected 
through specifically designed questionnaire. Research was prepared and consulted 
with relevant patient organization League against Rheumatism in Slovakia. Results: 
The sample (200 respondents) was predominantly female (57%) with diagnosis of 
RA (66%) followed by ankylosing spondylitis (17%). As many as 65% of the patients 
became permanently work disabled at the average age of 41, with full work disability 
being more common (36%) than partial disability (30%). The occurrence of sick leaves 
within preceding 12 months among actively working was 52% with an average length 
of 51 days. Three most frequently reported areas negatively affected by the disease: 
social activities (reported by 65% respondents), professional career (53%) and quality 
of a relationship with their partner (25%). Twenty-five percent of respondents had to 
change their jobs due to the disease. Average personal expenses of the treatment in 
the preceding 3 months were 76€ , traveling costs in the first place. Despite disease 
stabilization in the sample majority, 70% of respondents stated restrictive (51%) or 
very restrictive (19%) impact of the disease on their overall functioning. In the preced-
ing week, strenuous activities and sports became the most limited. The support from 
tively. cOnclusiOns: In this study of routine clinical practice in Bulgaria, only 4.5% 
of women initiating denosumab discontinued treatment within 24 months, compared 
with more than half of those initiating monthly oBPs.
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Objectives: Many studies prove non-compliance to medication to be one of the 
biggest problems in health care today. Non-compliance can lead to increased cost 
of care due to additional hospitalizations, emergency care, medication. These facts 
are relevant for patients with arthritis as the effects of non-compliance can increase 
the risk of acute crisis, pain and sick pays. Our objective was to examine the fac-
tors that can lead to non-compliance among patients with arthritis. MethOds: The 
Morisky 8-item Medication Adherence Questionnaire was applied to 96 patients with 
arthritis. After the ranking of the patients to the three groups – with low adherence, 
with medium adherence and with high adherence, those that were in the first group 
were asked about the factors that make them not compliant with the medication. 
The factors were grouped into two groups – subjective (expensive treatment, forget-
ting to take medication, difficulties to follow the regimen, etc.) and objective (ADRs, 
difficulties with the package, difficulties to find the prescribed medication in the 
pharmacy, etc.) Results: Thirty-one per cent were scored with low adherence, vary-
ing from 3 to 8 relevant to complete failure to take the prescribed drugs. The factors 
that were outlined were mainly objective – 52% - ADRs; 49% - difficulties to open the 
package. From the subjective factors 15% from the respondents rank the treatment as 
expensive and they answer that they cannot afford it to purchase the prescribed treat-
ment. cOnclusiOns: Drug treatment does not appear to be a significant problem in 
management of arthritis, as over 69 % of the patients were taking their medications 
all or most of the time. However the subjective factors can be demotivating for the 
patients and they have to be taken in mind during the patients’ consultation by the 
health care providers in order to be increased the rate of compliance.
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Objectives: Quality of life weights (utilities) are requested by many decision mak-
ers. In rare diseases the reliance on very small single arm trials makes it almost 
impossible to sensibly aggregate health-related quality of life (HRQL) data. This study 
presents a case study in hypophosphatasia (HPP), an ultra-rare disease, where two 
different methods were used to estimate utilities. MethOds: Study 1: Detailed case 
histories were developed which described the functional, symptom and HRQL burden 
for hypothetical patients with HPP (adults and children) through interviews with 
clinical experts (n= 6). Seven case histories, defined by predicted 6 minute walk test 
(6MWT) for those aged 5+ and the need for invasive ventilation for infants, were 
then assessed by experts (n = 9) using EQ-5D-5L. Study 2: A survey of patients with 
HPP and parents recruited through advocacy groups asked people to assess HRQL by 
EQ-5D-3L and also to report on mobility (as a proxy for the 6MWT). No infant states 
were included in study 2. Results: Study 1: Development of the case histories was 
challenging because of the experts’ unfamiliarity with 6MWT in clinical practice and 
their limited exposure to the possible broad range of patient severity. EQ-5D utilities 
were: infants < 5 on invasive ventilation = -0.09, no ventilation= 0.24; children/adults 
ranged from 0.86 (> 82% 6MWT) to 0.23 (< 46% 6MWT). Study 2: children’s (n= 9 parents) 
EQ-5D scores ranged from 0.79 (> 82% 6MWT) to -0.24 (< 46% 6MWT); and adults (n= 25) 
ranged from 0.51 (> 82% 6MWT) to -0.01 (< 46% 6MWT). cOnclusiOns: Two separate 
studies describe the HRQL impact of HPP in adults and children. Utility values reported 
by patients and parents were consistently lower than those reported by experts. Both 
studies have important limitations, including the sample size. On a practical level the 
QALY based system does not seem so well suited to decisions regarding orphan drugs.
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Objectives: Identification and review of used methods to derive patient utilities 
for health economic modelling in psoriatic arthritis (PsA) and ankylosing spon-
dylitis (AS) MethOds: A literature search of Embase, MEDLINE from 1996-2015 
was conducted to identify health economic, clinical studies that hold information 
about deriving utilities in PsA, AS. Additionally HTA submissions in PsA, AS were 
also screened. Publication inclusion was limited to in English language, biological 
therapy in PsA or AS. Results: In total the search retrieved 3,175 articles, of which 
124 fulfilled screening criteria. Most of the publications were screened for AS (n= 73), 
followed by PsA (n= 46) while five publications included both indications. Across 
studies baseline characteristics varied in age (Years, PsA: 35.5–65.0; AS: 24.4–61.0), 
disease duration (Years, AS: 0.7–30.2; PsA: 1.7–22.2) and gender distribution (Females, 
AS: 0–70%, PsA: 25–88%). No study was identified that used direct methods like time 
trade-off or standard gamble for utility derivation. Among generic measures SF-36 
(n= 27 for PsA, n= 55 for AS), EQ-5D (n= 10 PsA, n= 14 AS) were primarily used. In total 
45 different disease specific tools were identified (PsA, n= 30; AS, n= 15). The HAQ-DI 
(n= 36) and ASQoL (n= 21) were the most common tools in PsA, AS respectively. 
Among the cost-effectiveness studies 13 utility derivation algorithms in PsA and 
5 in AS were identified. EQ-5D was the most commonly used HRQoL instrument 
to derive utilities (PsA, n= 9; AS, n= 3). Most cost-effectiveness models used HAQ-DI 
in PsA while BASFI, BASDAI were used in AS to derive utilities. cOnclusiOns: 
Even though more publications were identified in AS, more utility derivation algo-
rithms were identified in PsA. However no standard process has been established 
